U.K. software developer Ultromics has raised $10 million (8.9 million euros) in financing from current shareholder Oxford Sciences Innovation and healthcare investor Nina Capital.
The company's EchoGo Core uses artificial intelligence to read echocardiograms, and it was cleared by the U.S. Food and Drug Administration (FDA) last November. Its next iteration, EchoGo Pro, is pending FDA clearance, according to the firm.
The company is working with U.S. clinics that are using EchoGo Core to better understand how the SARS-CoV-2 virus attacks the heart, it said.
